Melanoma: A model for testing new agents in combination therapies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-04-20

AUTHORS

Paolo A Ascierto, Howard Z Streicher, Mario Sznol

ABSTRACT

Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time. More... »

PAGES

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1479-5876-8-38

DOI

http://dx.doi.org/10.1186/1479-5876-8-38

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042671405

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20406483


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Biological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/grid.508451.d", 
          "name": [
            "Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ascierto", 
        "givenName": "Paolo A", 
        "id": "sg:person.01212502023.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Streicher", 
        "givenName": "Howard Z", 
        "id": "sg:person.0701321075.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701321075.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Melanoma Program, Yale University School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Melanoma Program, Yale University School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1054/bjoc.1999.1056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053146876", 
          "https://doi.org/10.1054/bjoc.1999.1056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.1999.1007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003939676", 
          "https://doi.org/10.1054/bjoc.1999.1007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006916541", 
          "https://doi.org/10.1038/nature08902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009288742", 
          "https://doi.org/10.1038/nature08833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-010-9206-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048622995", 
          "https://doi.org/10.1007/s10555-010-9206-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.438", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033148408", 
          "https://doi.org/10.1038/ng.438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033343259", 
          "https://doi.org/10.1038/nrc2468"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-009-0732-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004077836", 
          "https://doi.org/10.1007/s00262-009-0732-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-7-86", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022018262", 
          "https://doi.org/10.1186/1479-5876-7-86"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-04-20", 
    "datePublishedReg": "2010-04-20", 
    "description": "Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1479-5876-8-38", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "c-Kit inhibitors", 
      "advanced melanoma", 
      "immune modulators", 
      "introduction of interferon", 
      "new single agents", 
      "multi-modality treatment", 
      "reliable predictive biomarkers", 
      "selection of patients", 
      "adoptive cellular therapy", 
      "anti-angiogenesis agents", 
      "Validation of Patient", 
      "additional molecular targets", 
      "immunologic modulators", 
      "advanced disease", 
      "combination therapy", 
      "predictive biomarkers", 
      "IL-2", 
      "high success rate", 
      "individual patients", 
      "new agents", 
      "small molecule inhibitors", 
      "patients", 
      "single agent", 
      "response rate", 
      "anticancer modalities", 
      "cellular therapy", 
      "molecular targets", 
      "B-Raf inhibitors", 
      "success rate", 
      "molecule inhibitors", 
      "drug development", 
      "treatment", 
      "recent data", 
      "therapy", 
      "melanoma", 
      "mutant B-RAF", 
      "inhibitors", 
      "trials", 
      "B-Raf", 
      "agents", 
      "active agents", 
      "early stages", 
      "experimental treatments", 
      "chemotherapy", 
      "modulator", 
      "surgery", 
      "CD40", 
      "CTLA4", 
      "interferon", 
      "tumors", 
      "large subset", 
      "disease", 
      "biomarkers", 
      "modalities", 
      "new strategy", 
      "involvement", 
      "corresponding mutation", 
      "rate", 
      "greater selectivity", 
      "better understanding", 
      "standard approach", 
      "mutations", 
      "subset", 
      "response", 
      "target", 
      "protein", 
      "mutant proteins", 
      "resistance", 
      "mechanism", 
      "stage", 
      "promise", 
      "combination", 
      "identification", 
      "data", 
      "development", 
      "strategies", 
      "effective way", 
      "time", 
      "early 1990s", 
      "validation", 
      "progress", 
      "understanding", 
      "approach", 
      "new generation", 
      "radiation", 
      "introduction", 
      "selection", 
      "turn", 
      "model", 
      "generation", 
      "stakeholders", 
      "selectivity", 
      "way"
    ], 
    "name": "Melanoma: A model for testing new agents in combination therapies", 
    "pagination": "38", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042671405"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1479-5876-8-38"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20406483"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1479-5876-8-38", 
      "https://app.dimensions.ai/details/publication/pub.1042671405"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_520.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1479-5876-8-38"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-8-38'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-8-38'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-8-38'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-8-38'


 

This table displays all metadata directly associated to this object as RDF triples.

245 TRIPLES      21 PREDICATES      136 URIs      118 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1479-5876-8-38 schema:about N118d84a1edaf474ab7b23844b1070ab2
2 N2eff064759bd41e28325669d22dd432f
3 N680404468cbf470187737602f31745d8
4 N8bdfd26f401f4dbd949c94d94121cbd4
5 N8fecf6e90dde4ec2b55a1179b900b0cd
6 N928afe163acf44418d83f08f862a41fe
7 Nb382c51dbb0d4755872ea4ee6010d6ce
8 Nd7603f5363e2448b94142629817d1d62
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author N724fb101db404987a48bcc4926ed9419
12 schema:citation sg:pub.10.1007/s00262-009-0732-5
13 sg:pub.10.1007/s10555-010-9206-7
14 sg:pub.10.1038/nature00766
15 sg:pub.10.1038/nature08833
16 sg:pub.10.1038/nature08902
17 sg:pub.10.1038/ng.438
18 sg:pub.10.1038/nrc2468
19 sg:pub.10.1054/bjoc.1999.1007
20 sg:pub.10.1054/bjoc.1999.1056
21 sg:pub.10.1186/1479-5876-7-86
22 schema:datePublished 2010-04-20
23 schema:datePublishedReg 2010-04-20
24 schema:description Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf Ncc116d26da874831992ae28e8e1f31e0
28 Ne890ac0950b4486a8a3a31307a3a32ff
29 sg:journal.1032886
30 schema:keywords B-Raf
31 B-Raf inhibitors
32 CD40
33 CTLA4
34 IL-2
35 Validation of Patient
36 active agents
37 additional molecular targets
38 adoptive cellular therapy
39 advanced disease
40 advanced melanoma
41 agents
42 anti-angiogenesis agents
43 anticancer modalities
44 approach
45 better understanding
46 biomarkers
47 c-Kit inhibitors
48 cellular therapy
49 chemotherapy
50 combination
51 combination therapy
52 corresponding mutation
53 data
54 development
55 disease
56 drug development
57 early 1990s
58 early stages
59 effective way
60 experimental treatments
61 generation
62 greater selectivity
63 high success rate
64 identification
65 immune modulators
66 immunologic modulators
67 individual patients
68 inhibitors
69 interferon
70 introduction
71 introduction of interferon
72 involvement
73 large subset
74 mechanism
75 melanoma
76 modalities
77 model
78 modulator
79 molecular targets
80 molecule inhibitors
81 multi-modality treatment
82 mutant B-RAF
83 mutant proteins
84 mutations
85 new agents
86 new generation
87 new single agents
88 new strategy
89 patients
90 predictive biomarkers
91 progress
92 promise
93 protein
94 radiation
95 rate
96 recent data
97 reliable predictive biomarkers
98 resistance
99 response
100 response rate
101 selection
102 selection of patients
103 selectivity
104 single agent
105 small molecule inhibitors
106 stage
107 stakeholders
108 standard approach
109 strategies
110 subset
111 success rate
112 surgery
113 target
114 therapy
115 time
116 treatment
117 trials
118 tumors
119 turn
120 understanding
121 validation
122 way
123 schema:name Melanoma: A model for testing new agents in combination therapies
124 schema:pagination 38
125 schema:productId N587dce01b5534632aacb1edb6007075f
126 N65de683802e9430eb1f56013091940fa
127 Na2292d6fd29d43d49f5ca4cc80308686
128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042671405
129 https://doi.org/10.1186/1479-5876-8-38
130 schema:sdDatePublished 2022-09-02T15:54
131 schema:sdLicense https://scigraph.springernature.com/explorer/license/
132 schema:sdPublisher N2af417bed996403e873e228240de1f53
133 schema:url https://doi.org/10.1186/1479-5876-8-38
134 sgo:license sg:explorer/license/
135 sgo:sdDataset articles
136 rdf:type schema:ScholarlyArticle
137 N118d84a1edaf474ab7b23844b1070ab2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Antineoplastic Agents
139 rdf:type schema:DefinedTerm
140 N2af417bed996403e873e228240de1f53 schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 N2eff064759bd41e28325669d22dd432f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Clinical Trials as Topic
144 rdf:type schema:DefinedTerm
145 N587dce01b5534632aacb1edb6007075f schema:name doi
146 schema:value 10.1186/1479-5876-8-38
147 rdf:type schema:PropertyValue
148 N65de683802e9430eb1f56013091940fa schema:name dimensions_id
149 schema:value pub.1042671405
150 rdf:type schema:PropertyValue
151 N680404468cbf470187737602f31745d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Combined Modality Therapy
153 rdf:type schema:DefinedTerm
154 N724fb101db404987a48bcc4926ed9419 rdf:first sg:person.01212502023.44
155 rdf:rest Ne43f29cfbf7c4d659b67a42184adde0a
156 N8bdfd26f401f4dbd949c94d94121cbd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Signal Transduction
158 rdf:type schema:DefinedTerm
159 N8fecf6e90dde4ec2b55a1179b900b0cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Melanoma
161 rdf:type schema:DefinedTerm
162 N928afe163acf44418d83f08f862a41fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Na2292d6fd29d43d49f5ca4cc80308686 schema:name pubmed_id
166 schema:value 20406483
167 rdf:type schema:PropertyValue
168 Nb382c51dbb0d4755872ea4ee6010d6ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Models, Biological
170 rdf:type schema:DefinedTerm
171 Ncc116d26da874831992ae28e8e1f31e0 schema:issueNumber 1
172 rdf:type schema:PublicationIssue
173 Nd7603f5363e2448b94142629817d1d62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Antineoplastic Combined Chemotherapy Protocols
175 rdf:type schema:DefinedTerm
176 Ne43f29cfbf7c4d659b67a42184adde0a rdf:first sg:person.0701321075.74
177 rdf:rest Neb5d79ff5dbb41aa93d383a5c9c9fd1c
178 Ne890ac0950b4486a8a3a31307a3a32ff schema:volumeNumber 8
179 rdf:type schema:PublicationVolume
180 Neb5d79ff5dbb41aa93d383a5c9c9fd1c rdf:first sg:person.0706626451.72
181 rdf:rest rdf:nil
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
186 schema:name Oncology and Carcinogenesis
187 rdf:type schema:DefinedTerm
188 sg:journal.1032886 schema:issn 1479-5876
189 schema:name Journal of Translational Medicine
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01212502023.44 schema:affiliation grid-institutes:grid.508451.d
193 schema:familyName Ascierto
194 schema:givenName Paolo A
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
196 rdf:type schema:Person
197 sg:person.0701321075.74 schema:affiliation grid-institutes:grid.48336.3a
198 schema:familyName Streicher
199 schema:givenName Howard Z
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701321075.74
201 rdf:type schema:Person
202 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
203 schema:familyName Sznol
204 schema:givenName Mario
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
206 rdf:type schema:Person
207 sg:pub.10.1007/s00262-009-0732-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004077836
208 https://doi.org/10.1007/s00262-009-0732-5
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s10555-010-9206-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048622995
211 https://doi.org/10.1007/s10555-010-9206-7
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
214 https://doi.org/10.1038/nature00766
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/nature08833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009288742
217 https://doi.org/10.1038/nature08833
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/nature08902 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006916541
220 https://doi.org/10.1038/nature08902
221 rdf:type schema:CreativeWork
222 sg:pub.10.1038/ng.438 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033148408
223 https://doi.org/10.1038/ng.438
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/nrc2468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033343259
226 https://doi.org/10.1038/nrc2468
227 rdf:type schema:CreativeWork
228 sg:pub.10.1054/bjoc.1999.1007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003939676
229 https://doi.org/10.1054/bjoc.1999.1007
230 rdf:type schema:CreativeWork
231 sg:pub.10.1054/bjoc.1999.1056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053146876
232 https://doi.org/10.1054/bjoc.1999.1056
233 rdf:type schema:CreativeWork
234 sg:pub.10.1186/1479-5876-7-86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022018262
235 https://doi.org/10.1186/1479-5876-7-86
236 rdf:type schema:CreativeWork
237 grid-institutes:grid.47100.32 schema:alternateName Melanoma Program, Yale University School of Medicine, New Haven, CT, USA
238 schema:name Melanoma Program, Yale University School of Medicine, New Haven, CT, USA
239 rdf:type schema:Organization
240 grid-institutes:grid.48336.3a schema:alternateName Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
241 schema:name Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
242 rdf:type schema:Organization
243 grid-institutes:grid.508451.d schema:alternateName Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy
244 schema:name Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy
245 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...